Zacks Investment Research downgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a buy rating to a hold rating in a research note issued to investors on Monday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
A number of other research analysts have also commented on the company. Roth Capital set a $6.00 target price on Actinium Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, October 10th. Oppenheimer set a $5.00 target price on Actinium Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, November 28th. Maxim Group restated a buy rating and issued a $3.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, August 14th. Finally, B. Riley set a $3.00 target price on Actinium Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $3.55.
Shares of NYSEAMERICAN ATNM opened at $0.47 on Monday. Actinium Pharmaceuticals has a one year low of $0.33 and a one year high of $0.87.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Actinium Pharmaceuticals by 6.4% during the third quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock worth $1,909,000 after acquiring an additional 154,403 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in Actinium Pharmaceuticals during the third quarter worth $816,000. PNC Financial Services Group Inc. acquired a new position in Actinium Pharmaceuticals during the third quarter worth $617,000. Renaissance Technologies LLC raised its stake in Actinium Pharmaceuticals by 1,269.5% during the second quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 359,205 shares in the last quarter. Finally, Virtu Financial LLC raised its stake in Actinium Pharmaceuticals by 103.1% during the third quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 99,318 shares in the last quarter.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Read More: How to Calculate Compound Annual Growth Rate (CAGR)
Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.